The purpose of a new study published in the Photodermatology, Photoimmunology & Photomedicine was to determine the action spectra and minimal urticaria dose (MUD) and to tailor a treatment regimen graded according to disease severity in a series of patients with solar urticaria (SU). Here, 11 patients, between 5 and 60 years of age, were treated with various combinations of antihistamines and leukotriene receptor antagonist; among these seven were females and four were males. It was found that all patients were sensitive to visible light. Three patients were sensitive to UVA, and one patient was sensitive to UVB. While two patients experienced a spontaneous remission without treatment, one declined treatment. The remaining eight patients were managed by a combination of antihistamines (desloratidine, fexofenadine, cetirizine HCl) and a leukotriene receptor antagonist (montelukast). Subsequently, 7 of the 8 patients experienced a sustained remission of signs and symptoms. Hence, it was concluded that photoprovocation for SU with determination of action spectra and MUD enables specifically tailored treatment regimens consisting of combinations of antihistamines and leukotriene receptor antagonist.